News & Updates
Filter by Specialty:
Show Multimedia Only

Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022
    byRoshini Claire Anthony
        Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.









